Trend Analysis for Sterile Manufacturing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Trend Analysis for Sterile Manufacturing
A Pharmaceutical Technology survey examines capacity expansions, outsourcing practices, innovation levels, and the role of quality by design in sterile manufacturing and aseptic processing.


Pharmaceutical Technology



JUNIOR GONZALEZ/GETTY IMAGES
Sterile manufacturing and aseptic processing are important in pharmaceutical manufacturing. To gain a perspective, Pharmaceutical Technology conducted a survey to gauge investments in manufacturing capacity, outsourcing practices, the level of innovation, and the influence of quality by design (QbD). The survey found a fairly strong level of investment in sterile manufacturing and aseptic processing in 2008 and slightly lower levels planned for 2009. Respondents were almost evenly divided in their decision whether to keep manufacturing in house or to outsource and were generally satisfied with the level of innovation in equipment and machinery. And QbD is playing a significant role in companies' sterile-manufacturing practices.

Capacity expansions


Figure 1
More than half, or 58.3%, of respondents said that their companies added capacity for sterile manufacturing or aseptic processing in 2008 (see Figure 1). Almost 40% of respondents said that their companies were planning to add capacity in 2009 or 2010 (see Figure 2).


Figure 2
For those companies that added capacity in 2008, 46% added capacity for finished-product manufacturing. Fifteen percent increased capacity for drug-substance manufacturing, and 39% added capacity in both areas. A similar distribution holds for companies planning to add capacity in 2009 or 2010. Of those companies, 44% plan to add capacity for both drug-substance and finished-product manufacturing. Thirty-nine percent will add capacity for finished-product manufacturing only, and 17% plan to add capacity for drug-substance manufacturing only.


Figure 3
The overwhelming majority of respondents did not have capabilities for sterile manufacturing or aseptic processing for cytotoxic or high-potency products. Approximately 62% of companies responding to the survey did not perform sterile manufacturing or aseptic processing of these products, and 38% did (see Figure 3). Of the companies that did not perform cytotoxic or high-potency manufacturing, only 13% were considering adding this capability.

Outsourcing


Figure 4
Respondents were almost evenly divided regarding whether they kept sterile manufacturing or aseptic manufacturing in house or outsourced. Forty-eight percent of respondents said that their companies outsource sterile manufacturing or aseptic processing, and 52% do not outsource (see Figure 4). Of those companies that do outsource, 57% outsource both drug-substance and finished-product manufacturing (see Figure 5). Thirty-three percent outsource manufacturing for finished products only, and 9% outsource only drug-substance manufacturing.


Figure 5
The number one reason for outsourcing is companies believe that it is more cost-effective than producing a product internally. Almost half of all respondents, or 47%, said that outsourcing was more cost-effective than captive production. The other reasons for outsourcing are limited or no internal manufacturing capacity (39% responded thus) and an increase in projects requiring sterile manufacturing (35% responded thus).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here